# US 2014/0193463 A1 · Peptide for inhibiting dipeptidyl-peptidase iv

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0193463 A1
- Document ID: US20140193463A1
- Status: Published application
- Kind: A1
- Application number: 13/733,903
- Filed: 2013-01-04
- Published: 2014-07-10
- Earliest claimed: 2013-01-04
- Assignees: China Medical University
- Applicants: China Medical University
- Inventors: Kuo-Chiang HSU; Kit-Pan HO; Shih-Li HUANG; Chia-Ling JAO
- Web page: https://patentgrep.com/patent/US20140193463A1

## CPC

- C07K 5/1008: {the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala}
- A61K 38/014: {from connective tissue peptides, e.g. gelatin, collagen}
- A61K 38/07: Tetrapeptides
- C12N 9/485: {Exopeptidases (3.4.11-3.4.19)}
- C12Y 304/14005: Dipeptidyl-peptidase IV (3.4.14.5)
- A61K 35/60: Fish, e.g. seahorses; Fish eggs
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

A method for inhibiting dipeptidyl-peptidase IV is provided and includes administering a peptide to the dipeptidyl-peptidase IV, in which the peptide is isolated from a gelatin hydrolysate produced by enzymatic digestion with alcalase (ALA), bromelain (BRO), and flavourzyme (FLA).

## Claims

### Claim 1

A method for inhibiting dipeptidyl-peptidase IV comprising:
administering an effective amount of a peptide to the dipeptidyl-peptidase IV, wherein the peptide is isolated from a gelatin hydrolysate produced by enzymatic digestion with bromelain (BRO), or flavourzyme (FLA) and comprises four amino acid residues with an amino acid sequence of
Gly-Pro-X3-X4 (SEQ ID NO: 1), wherein
X3 is alanine or glycine; and
X4 is glutamate or alanine.

### Claim 2

(canceled)

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The method according to claim 1, wherein the peptide is isolated from a fraction of the gelatin hydrolysate fractionated by ultrafiltration with 1 kDa and 2.5 kDa cutoff membranes.

### Claim 5 (depends on 4)

The method according to claim 4, wherein the fraction comprises the fractionated gelatin hydrolysate permeating through the 1 kDa cutoff membrane.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the gelatin is a salmon skin gelatin.

### Claim 7 (depends on 6)

The method according to claim 6, wherein the salmon is an Atlantic salmon (Salmo salar).

### Claim 8 (depends on 1)

The method according to claim 1, wherein the method is administered in vivo or in vitro.

### Claim 9

(canceled)

### Claim 10

(canceled)

### Claim 11

A method for treating type 2 diabetes, comprising administering an effective amount of a peptide to an animal, wherein the peptide isolated from a gelatin hydrolysate produced by enzymatic digestion with bromelain (BRO), or flavourzyme (FLA) and comprises four amino acid residues and has an amino acid sequence of
Gly-Pro-X3-X4 (SEQ ID NO: 1), wherein
X3 is alanine or glycine; and
X4 glutamate or alanine.

### Claim 12 (depends on 11)

The method according to claim 11, wherein the animal is a mammal.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the mammal is a human being.

### Claim 14

A pharmaceutical composition comprising a peptide isolated from a gelatin hydrolysate produced by enzymatic digestion with bromelain (BRO), or flavourzyme (FLA) includes four amino acid residues having an amino acid sequence of
Gly-Pro-X3-X4 (SEQ ID NO: wherein
X3 is alanine or glycine; and
X4 is glutamate or alanine.

### Claim 15 (depends on 14)

The pharmaceutical composition according to claim 14, further comprising a pharmaceutically suitable carrier.

### Claim 16 (depends on 14)

The pharmaceutical composition according to claim 14, further comprising a pharmaceutically acceptable salt.

### Claim 17 (depends on 14)

The pharmaceutical composition according to claim 14, further comprising a pharmaceutically acceptable excipient.

### Claim 18 (depends on 14)

The pharmaceutical composition according to claim 14, wherein the pharmaceutical composition is in the form of a tablet, capsule, pill, syrup, suspension, solution, powder, granule, emulsion, microsphere, injectable solution or solid lipid nanoparticles.

### Claim 19 (depends on 14)

The pharmaceutical composition according to claim 14, wherein the pharmaceutical composition is in the form of a feed, a drink, a nutrient supplement, a food, or a healthy food.